Form 4: Compass Therapeutics CAO Neil Lerner Granted Equity

Compass Therapeutics' Chief Accounting Officer, Neil Lerner, was granted 62,500 restricted stock units and 435,000 stock options as part of an equity compensation package.

Summary

• Neil Lerner, Chief Accounting Officer of Compass Therapeutics, Inc. (CMPX), reported the acquisition of equity securities.
• On January 2, 2026, Lerner was granted 62,500 Restricted Stock Units (RSUs) at a price of $5.17 per share.
• Each RSU represents a contingent right to receive one share of common stock and is subject to service-based vesting conditions.
• The RSUs vest in four equal annual installments, with the first vesting scheduled for January 2, 2027.
• Following this transaction, Lerner beneficially owns 382,500 shares of common stock, including the unvested RSUs.
• Additionally, on January 2, 2026, Lerner was granted 435,000 stock options with an exercise price of $5.17.
• These options vest over 48 substantially equal monthly installments, commencing on February 2, 2026.
• The stock options have an expiration date of January 2, 2036.

Sentiment

Score: 7

Explanation: The equity grants align the Chief Accounting Officer's long-term interests with those of shareholders, serving as a retention and performance incentive. This is a positive for corporate governance and executive motivation, though it does not represent a direct cash investment by the insider.

Positives

• The equity grants align the Chief Accounting Officer's long-term interests with those of shareholders, promoting retention and performance.
• The vesting schedules for both RSUs and stock options encourage sustained executive commitment to the company's performance over several years.

Negatives

• No direct cash investment by the officer was reported, as these are compensation grants rather than open market purchases.

Future Outlook

The grants are structured with future vesting dates, indicating an expectation of continued service and performance from the Chief Accounting Officer.

Industry Context

Equity compensation, including restricted stock units and stock options, is a standard practice in the biotechnology and pharmaceutical industries to attract, retain, and incentivize key executives, aligning their interests with long-term shareholder value.

Comparison to Industry Standards

• The structure of these equity grants, involving both RSUs and stock options with multi-year vesting schedules, is consistent with typical executive compensation packages observed across the biotechnology sector.
• The exercise price of the options matching the RSU grant price ($5.17) is standard for grants made on a specific date, reflecting the market value at the time of grant.

Stakeholder Impact

• Shareholders: The grants align executive incentives with shareholder value creation over the long term, potentially leading to improved company performance.
• Employees (specifically Neil Lerner): The grants provide significant long-term compensation and a direct stake in the company's success, enhancing retention and motivation.

Next Steps

• Neil Lerner's continued service with Compass Therapeutics, Inc. is required for the vesting of the granted RSUs and stock options.

Key Dates

Recommendation

This Form 4 reports routine equity compensation grants to a key executive, which aligns management incentives with shareholder value over the long term. It does not provide new information warranting a change in investment thesis or a strong buy/sell recommendation, as such grants are a standard part of executive compensation.

Keywords

Compass Therapeutics, CMPX, Neil Lerner, Chief Accounting Officer, Restricted Stock Units, RSU, Stock Options, Equity Grant, Insider Transaction, Executive Compensation, Vesting